Septin expressions are altered in cancer cells and exhibit poor prognoses in malignancies. As the 26 first approach to develop a septin filament targeting agent, we optimized the structure of 27
Pharmacologic agents to target septins have remained elusive, largely because the oligomeric 51 structural configurations of septins pose difficult challenges in designing therapies. 52
In this study, we investigated the impact of individual septins on the survival of patients 53
with cancers of the pancreas, breast, lung, kidney, or liver cancer or with melanoma. To determine 54 the effect of septins on survival, we used the Human Protein Atlas (HPA), and publically available 55 transcriptional data and tools available at R2:Genomics Analysis and Visualization Platform 20 56
(https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). We describe a potent septin modulator, UR214-9, 57
which disrupts structural organization of septin-2 and septin-9 as well as of β-actin, and controls 58 cancer cell proliferation and tumor growth. We have employed molecular docking techniques to 59 investigate how UR214-9 and its analogs interact with the elements of the GDP binding domain, 60
and of the known FCF binding pocket. To identify how gene expression is impacted by UR214-9, 61
and thereby characterize its off-target liabilities, we have conducted transcriptome analyses of 62 UR214-9 treated breast and pancreatic cancer cells. In summary, our studies present UR214-9, 63
as a potent and novel septin filamental modulator and demonstrate that the dismantling of septin 64 structures in pancreatic, ovarian and breast cancer cells by UR214-9 can be an effective 65 therapeutic strategy. 66 67 68
Results 69 70
Enrichment of septins correlates with decreased survival in patients with cancer 71
Publically accessible microarray data bases of pancreatic cancer and ovarian cancer patients cancer, grouped by the extent of septin-2 expression (from microarray data available at 82 https://hgserver1.amc.nl/cgi-bin/r2/main.cgi 20 and Human Protein Atlas 21 , show that septin-2 mRNA 83 enrichment significantly (p=0.0011) correlates with increased mortality ( Figure 1D -left). Similarly, 84 enrichment of septin-7 and -9 correlates with increased mortalities in pancreatic cancer patients 85
( Supplementary Figure 1 ). Septin-2 enrichment is also an unfavorable factor for patients with 86
breast (Figure-1D , middle, p=3.9e-3) and ovarian cancer ( Figure-1D , right, p=0.011). Analysis of 87 the survival prospects based on other septins indicate that septin-7 enrichment was found to be 88 unfavorable for the patients diagnosed with malignancies of breast (p=0.0079) (Supplementary 89 Figure-1 ). 90 91 UR214-9 causes septin-2 catastrophe in cells 92
The chemical structure of UR214-9 is shown in Figure- 2A. UR214-9 was obtained by the 93 structure-activity relationship guided optimization of FCF. Incorporation of a group of fluorine 94 atoms on phenyl ring and installation of a chlorine atom at C-6 of pyridine ring made UR214-9 a 95 potent disruptor of septin's filamental structure. Confocal microscopy at higher resolution (60x2) 96
was employed to determine the impact of DMSO, FCF (+ve control) and UR214-9 on the structural 97 arrangement of septin-2, 6, 7 and -9 in a panel of BXPC-3, CAPAN-1, Panc-1 (pancreatic) and 98
JIMT-1(breast) and SKOV-3 ovarian cancer cells. While FCF seems to strengthen the septin-2 99 filaments in BXPC-3 cells (Figure-2B, left-lower), Septin-2 needles in PANC-1 were disarranged 100 and translocated at the cell-surface after UR214-9 treatment (1uM) ( Figure 2C , lower left).
101
Similarly, the septin-2 needles in JIMT-1 cells after drug treatment showed structural disruptions 102 and relocation to nuclear periphery (Figure-2C, right-lower). Next, the confocal microscopy was 103 employed to investigate the response of other septin family members in PANC-1 cells upon 104 treatment with UR214-9. Septin-7 showed reduced expression whereas septin-9 showed 105 disarrangement of filamental structure ( Supplementary Figure-2 ). Septin-4, -6, did not exhibit 106 clear filamental structures and showed punctate staining instead, which was either reduced in the 107 treatment group compared to DMSO treated control or the drug effect was inconclusive (data not 108 shown). Similarly, UR214-9 treated JIMT-1 breast cancer cells showed strong structural 109 disarrangement and relocation of septin-2 on the periphery of nucleus (Figure-2 , right). JIMT-1 110 cells did not exhibit defined septin-7 structures, and therefore, the effect of UR214-9 on septin-7 111 remains ambiguous ( Supplementary Figure-2 , lower left). However, the confocal microscopy of 112
PANC-1 and JIMT-1 cells treated with UR214-9 exhibited clear disarrangement in septin-9 113 filament structures ( Supplementary Figure-2 , lower right). Whether UR214-9 treatment alters 114 expression of septin family of proteins was investigated by immunoblotting the total cell-lysates 115
of PANC-1, MDA-MB-231, JIMT-1 and MCF-7 cancer cells. The immunoblots were probed with 116 validated septin-2, 6,7 and -9 antibodies. In PANC-1 cells, septin-9 expression was completely 117
inhibited intriguingly, while expression of septin-2, -6 and -7 were unaffected (Figure-2D). Similarly, 118
western blot analysis of MDA-MB-231, JIMT-1 and MCF-7 cells showed that UR214-9 does not 119 alter the protein expression levels of septin-2,6 and -9 family of proteins ( Figure-2E ) even though 120 their filamental structures are overwhelmingly disrupted. Septin catastrophe phenomenon in 121 cancer cells was further validated using SKOV-3 ovarian cancer cells that upon treatment with 122 UR214-9 (1µM, 48hours) showed complete disruption of septin-2 filaments wherein septin-2 123 appears to have relocated to cell surface after drug exposure ( Figure-2F ). Further examination of 124 septin-6, 7 and -9 structures in drug treated SKOV-3 cells showed reorganization of septin-9 125
( Figure In Silico docking shows key interactions of UR214-9 with septin-2 137
Docking experiments to investigate the potential binding mode of UR214-9 and related 138 compounds (including FCF) were performed. UR214-9 and its analogs are smaller in size and 139 similar in structure and symmetry; they consist of a central urea group flanked by two lipophilic 140 substituted aromatic rings. Compounds UR214-8, 9, and 10 are the most active compounds that 141
we have developed; taking this into account, we hypothesized that they could share a similar 142 binding mode (the structure of compounds UR214-8, 9 and 10 are shown in Supplementary 143 Figure 3 ). Thus, compounds FCF, UR214-8, UR214-9, and UR214-10 were docked into the 144 nucleotide binding site of PDB ID 2QNR, which is the highest quality structure of a septin-2 dimer 145 complex available 23 . Upon visual inspection of the docking poses, two sets of low energy poses 146
("set A, upper and lower" and "set B, upper and lower") were identified in which all highly active 147 compounds are able to adopt similar conformations. The two sets are similar to each other in that 148
the three main portions of the molecules -the central urea moiety, the pyridine and the phenyl 149
ring -are in roughly the same area, with the pyridine ring taking the place of the guanine in GDP 150
( Figure 4 ). In set A, the pyridine nitrogen atom is seen taking the place of the guanine carbonyl 151 oxygen atom, making a hydrogen bond with the backbone of G241 of chain A. ICM scores of set-152
A were found to be compound UR214-8:-8.85, compound UR214-9: -8.59, compound UR214-10: 153 -10.4 and FCF: -7.21 indicating stronger binding energy of the synthesized analogs than the 154 parent FCF. Set B appears to be identical to a previously reported docking pose for FCF in the 155 same structure template, obtained with the Autodock software 23 . In Figure-4C and D, the identity 156 of amino acid residues interacting with atoms of UR214-9 or its analogs are shown. 157 158 159 UR214-9 impairs cancer cell viability and blocks cell cycle progression 160
Treatment with UR214-9 reduced the viability of human pancreatic cancer cells (BXPC-3 and 161 PANC-1) cells ( Figure 4A ) during 72 hours of treatment. PANC-1 and BXPC-3 cells upon 162 treatment with UR214-9 exhibited a large population of non-viable cells based upon staining by 163
the Live-Dead cell kit and by flow cytometry following 72 hours of treatment ( Figure 4B and -4C).
164
Given the role of septins in the cell cycle process, we analyzed the effect of UR214-9 on cell cycle 165 progression of PANC-1 and BXPC-3 pancreatic cancer cells at a non-cytotoxic concentration of 166
100nM. Treatment with UR214-9 at 100nM dose caused minor S-phase arrest in PANC-1 while 167 BXPC-3 cells showed no change in cell cycle distribution at the non-toxic doses (Supplementary 168 Figure-2A ). Increasing the dose to 3µM concentration of UR214-9 caused overwhelming arrest in 169 G1 phase (~95% compared to 21%) of BXPC-3 cells, while PANC-1 cells showed complete arrest 170
in sub-G1/G0 phase (data not shown). Similarly, JIMT-1 cells treated with an increased dose (3µM) 171 of UR214-9 exhibited G1 phase arrest and showed largely increased accumulation in G0-phase 172
( Supplementary Figure-2B ) 173 174 175 176
Analysis of cell cycle protein expression 177
The spotted antibody array was employed to simultaneous study multiple cell-cycle related 178 proteins expressed in drug treated or naïve PANC-1 cells. Measurement of relative photon counts 179
showed that Cullin-3, glycogen synthase kinase-3 (GSK-3b), p19ARF, 14.3.3.Pan, APC11, APC2, 180
ATM, C-able, CD14Aphsophatase, CDC25C, CDC34, CDC37, CDC47, CDC7, CDH1, CDK1 and 181 CDK-3 were the most expressed and affected proteins in the treated vs naïve PANC-1 182 considering >2.0 fold change as meaningful ( Supplementary Figure-3C ). β-actin showed the most 183 pronounced expression but expression levels remained unchanged after treatment. On the other 184 hand, Cullin-3 showed most pronounced upregulation in the treated versus naïve PANC-1 cells 185
( Supplementary Figure-3 , upper). Cullin-3, a member of the cullin-based ubiquitin ligase family 186
interacts with Hrt1 and BTB domain containing proteins. The resulting complex functions as a 187
Cullin3-based E3 ligase to bring specific substrates to ubiquitinylation and degradation 24 188
indicating the role of septins in suppression of cullin-3 mediated ubiquitinylation and subsequent 189 degradation. 190 191 192
UR214-9 treatment slows the growth of HER2 +xenograft tumors 193
Septin-2 regulates HER2 expression in gastric cancer cells 25 . HER2 is over-expressed in diverse 194 variety of malignancies [25] [26] [27] and is known to promote tumor development, progression, metastasis 195 and chemoresistance 28 . Septins are shown to protect and stabilize HER2 receptor at the plasma 196 membrane of tumor cells to perpetuate the HER2 orchestrated tumorigenesis 29 . We postulated 197 that targeting septin-2 can potentially emerge as a novel approach to control HER2 orchestrated 198 tumorigenesis. A MTS assay showed that UR214-9 treatment reduced the growth of BXPC-3 199
and PANC-1 pancreatic cancer dose dependently by 48 th hour of drug exposure (Figure-5A ).
200
Treatment with UR214-9[3µM] created 29.4% dead cells during 48 hours of drug exposure when 201 the total population of BXPC-3 cells was analyzed by Live-dead kit (Invitrogen Inc). Similarly, 202 PANC-1 cells presented over 38% dead-cell population upon treatment with UR214-9 [3µM]. Next, 203
we determined the impact of UR214-9 treatment on pancreatic cancer xenograft tumor growth in 204
vivo. Mice xenografted with HER2+ PANC-1 cells showed significantly delayed growth (p<0.0001) 205
( Immunoblot analysis of the total cell lysates of pancreatic cancer cells PANC-1 (HER2+), 213
cells treated with UR214-9 for 72 hours showed a dose-dependent decrease in HER2 expression 214
in PANC-1 ( Figure 6A , upper). STAT3 phosphorylation is a down-stream readout of HER2 215 activation 33 , accordingly UR214-9 treatment also reduced phosphorylated STAT-3 in PANC-1 216
( Figure 6A We have recently shown that septin-2 is highly 219 overexpressed in ovarian cancer 30 . Similar to JIMT-1 and PANC-1 cell-lines, SKOV-3, a platinum 220 resistant ovarian cancer cell-lines is characterized by HER2 amplification 31-32 . We, therefore 221 employed SKOV-3 cell-line derived xenografts to validate the antitumor efficacy of UR214-9 222 against HER2 amplified xenograft tumors. To further ascertain the outcome of the combination of 223 UR214-9 with Herceptin, mice were additionally treated with Herceptin alone or in combination 224 with UR214-9. As shown in the Figure-6D , both UR214-9 and Herceptin controlled the growth of 225
tumors. The combination clearly, controlled the tumor growth to a greater degree than both the 226 drugs alone. The real benefit of combination of UR214-9 with Herceptin became apparent when 227 treatments were stopped and tumors were allowed to grow. As shown in the Figure-6D while 228
tumor sizes in UR214-9 and Herceptin group reached the average size in control when the 229 treatments were stopped, the combination maintained greater control over tumor growth 230
(combination p<0.0001**** vs p=0.0004*** and 0.0001*** for vehicle vs UR214-9 and Herceptin).
231
When extracted tumors were weighed, the combination group exhibited presence of smaller 232 tumors, whereas, both the UR214-9 and Herceptin group produced the tumors that matched the 233 average size seen in vehicle group (Figure-6E ). 234 235
Whole transcriptome analysis reveals that UR214-9 is target selective 236
RNA-Seq was performed in the JIMT-1 and Panc-1 cell lines with three treatment groups (10nM 237
Afatinib, 1µM UR214-9, and DMSO) of four replicates each. The samples were sequenced to an 238 average depth of 58 million reads and greater than 90% of the read data for each sample aligned 239
uniquely to the human reference genome (hg38) after adapter and quality trimming. The drug 240
treatments were compared to the control group and differentially expressed genes were 241 determined (adjusted p-value < 0.05). There were 1236 (713 up and 523 down) dysregulated 242 genes between Afatinib treatment and control ( Figure 7A and 7C). The ENRICHR webtool was 243 used to determine that the upregulated genes (ALPP, TRIM29, CYP1A1) are associated with 244 extracellular matrix organization and cadherin binding, while the down regulated genes (EGR1, 245 DUSP6, HMGA2, etc.) are associated with purine metabolism and ribosome biogenesis. 246
Conversely, only 11 (7 up and 4 down) genes were called dysregulated between UR214-9 247 treatment and control ( Figure 7B and 7D). In terms of the PANC-1 cell line, there were only two 248 genes (COL13A1 and PRSS22) determined to be significantly differentially expressed upon 249
Afatinib treatment compared to the control group and no differentially expressed genes was called 250 between UR214-9 and the control. Docking experiments to investigate the potential binding mode of 9 and related compounds were 279 performed using Molsoft's ICM software package (v. 3.8-7). The molecules are rather small and 280 somewhat symmetric (consisting of a central urea group flanked by two lipophilicly substituted 281 aromatic rings). We assumed that since compounds 8, 9, and 10 are the most active ones, that 282 they might share a similar binding mode. Thus, compounds FCF, UR214-8,-9, and -10 were 283
docked into the nucleotide binding site of PDB ID 2QNR, which is the highest quality structure of 284 a septin-2 dimer complex available to date 23 . Receptor preparation (based on the GDP binding 285 site in chain A) and ligand construction was performed within ICM using standard settings. ICM 286 scores for each compound and their poses were calculated and compared with FCF. The 287 compounds were docked with the "dock table" functionality, with a setting for effort of 2.0 and 20 288 poses per compound. Upon visual inspection of the docking poses, two sets of low energy poses 289
("set A" and "set B") stood out, in which the highly active compounds are able to adopt similar 290 conformations 23 . 291 292 293
Cell Viability and cell cycle analysis, 294
Cell viability of PANC-1, BXPC-3 and CAPAN-1 pancreatic cancer cells treated with UR214-9 295
was measured using the Cell Titre96 R Aqueous One Solution Cell Proliferation Assay (Promega 296
Corp., catalog number: G3580) following the procedure published earlier. The Live/Dead dye kit 297
(Invitrogen Coro., catalog number: L34975) was used to estimate live and dead cell population in 298
PANC-1 and BXPC-3 pancreatic cancer cells treated with UR214-9 or vehicle. Briefly, cells were 299 treated with vehicle or UR214-9 (3µM) for 72 hours. Cells were harvested by trypsinization, fixed 300
and permeabilized using Fixation-Permeabilization reagent (prepared by diluting the concentrate 301
in the diluent in the ratio 1: 3) (Biogem Inc., diluent: catalog number 92160-00-160 and 302 concentrate catalog number: 2550-00-50) and stained with Live/dead dye for one hour. The cells 303
were centrifuged at 1000 rpm for 5 minutes and pellets were washed and spun down three times 304 with DPBS. The cells were analyzed by a flow cytometer and relative live and dead cell population 305
was calculated by inputing equal number of cells in both vehicle and control group. 306
For cell cycle analysis, BXPC-3 and PANC-1 and JIMT-1 cells (100,000/well) were seeded 307 overnight in a 6 well dishes and allowed to adhere overnight. Media was replaced with fresh 308 complete medium supplemented with DMSO or UR214-9 (100nM and 3µM) and cells were 309
incubated for 72 hours. The media containing the drugs was removed and cells were washed 310 twice with PBS and trypsinized gently. The cells were collected in 15 mL tubes, complete DMEM 311 media was added to block trypsin and cells were centrifuged. The supernatants were removed 312 and cells were gently treated with 70% cold-EtOH for 30 minutes. The fixed cells were centrifuged 313 and the pellets obtained were collected in flow cytometry tubes and stained with preformulated 314 PI/RNase solution (Cell Signaling Technology, catalog number: 4087s) for 30 minutes. The PI 315
content was analyzed using a flow cytometer. Data was processed using Flowjo software. 316 317
Cell cycle protein expression 318
Cell Cycle Antibody Array (FullMoon BioSystems Inc, catalogue number: ACC:058), a high-319
throughput ELISA based antibody array, designed for qualitative/semi-quantitative protein 320 expression profiling was employed to investigate the protein changes after drug treatment. Confocal analysis of septin disarrangement 331
To determine the impact of UR214-9 treatment on Septin-2 structure in cells, PANC-1 or JIMT-1 332 cells were seeded on glass slides and allowed to adhere overnight. The media was replaced with 333 complete DMEM media supplemented with DMSO or UR214-9 (1µM and 70nM) and cells were 334 incubated for 48 hours. Media was replaced again with new complete medium and fixed with 335 neutral buffered formalin for 15 minutes at 4 0 C. Media was removed and cells were washed 336 repeatedly with PBST (5x 5mL). The cells were stained with Septin-2 antibody (Sigma Aldrich, 337
catalog number: HPA018481) in PSB overnight at 4 0 C. Media was removed again and cells were 338
washed with 2x5mL PBST. The cells were stained with fluorescence linked secondary antibody 339
for 1hr under dark. Slides were washed repeatedly in dark for 7x5mL PBST, mounting medium 340 containing DAPI (Vector labs) were applied and covered with glass slide. The slides were stored 341 in dark at 4 0 C till analysis. Confocal images were obtained and processed essentially as published 342 earlier 34 Xenograft studies to evaluate antitumor response of UR214-9 355 NSG mice were implanted in their left flank with 1 million PANC-1 (HER2+, n=12), JIMT1 (number 356 of animals=10) and SKOV-3 (number of animals=10) cells each in matrigel:media (1:1). Mice 357
were randomized, identified with ear punches and subdivided into vehicle and treatment groups 358 when tumors were found palpable. Both JIMT1 and SKOV-3 formed aggressive tumors within a 359
week and were treated with vehicle or UR214-9 (25mg/kg, IP, seven days a week). PANC-1 360
formed slow growing tumors and when tumors reached length exceeding 5mm, the treatment was 361 started. A group of SKOV-3 cells were also treated with Herceptin or Herceptin+UR214-9. The 362 vehicle formulation was: 40% Hydroxypropyl-beta-cyclodextrin [Acros Organics] & solutol HS15 363
(Sigma] in sterile water). 25mg/kg equivalent of UR214-9 (1uL=200ug in DMSO) was dissolved 364
in 600uL PBS+400uL of the vehicle and vortexed to obtain a clear suspension. Tumor burden and 365
animal weight was measured manually by digital calipers on weekly or biweekly routine. Tumor 366 volume was calculated using the formula ½(L x W^2) where L is a longest diameter and W is the 367 widest width. Statistical difference between the vehicle and treatment groups was analyzed by 368
GraphPrism-8 software using one way annova. P<0.05 was considered significant. Mice after the 369 treatment period were euthanized and tumors were resected, weighed and frozen in liquid 370 nitrogen. A portion of the tumors from the control and treatment groups were fixed in neutral 371 buffered formaldehyde and paraffin embedded. 5uM thickness tissues slides were prepared for 372 histochemistry. 373 374 mRNA Sequencing 375 The total RNA concentration was determined with the NanopDrop 1000 spectrophotometer 376
(NanoDrop, Wilmington, DE) and RNA quality assessed with the Agilent Bioanalyzer (Agilent, 377
Santa Clara, CA) 35 . The TruSeq Stranded mRNA Sample Preparation Kit (Illumina, San Diego, 378
CA) was used for next generation sequencing library construction per manufacturer's protocols. 379
Briefly, mRNA was purified from 200ng total RNA with oligo-dT magnetic beads and fragmented. 380
First-strand cDNA synthesis was performed with random hexamer priming followed by second-381 strand cDNA synthesis using dUTP incorporation for strand marking. End repair and 3` 382 adenylation was then performed on the double stranded cDNA. Illumina adaptors were ligated to 383 both ends of the cDNA, purified by gel electrophoresis and amplified with PCR primers specific to 384 the adaptor sequences to generate cDNA amplicons of approximately 200-500bp in size. The 385
amplified libraries were hybridized to the Illumina single end flow cell and amplified using the cBot 386 (Illumina, San Diego, CA). Single end reads of 75nt were generated for each sample using 387
Illumina's NextSeq550 36 . 388 389 390
Whole transcriptome data analysis 391
Raw reads generated from the NovaSeq6000 sequencer were demultiplexed using bcl2fastq 392 version 2.19.0. Quality filtering and adapter removal are performed using Trimmomatic-0.36 with 393 the following parameters: "TRAILING:13 LEADING:13 ILLUMINACLIP:adapters.fasta:2:30:10 394 SLIDINGWINDOW:4:20 MINLEN:35" Processed/cleaned reads were then mapped to the Homo 395 sapiens reference sequence (GRCh38, hg38) with STAR-2.6.0c given the following parameters: 396
"--twopassMode Basic --runMode alignReads --genomeDir ${GENOME} --readFilesIn ${SAMPLE} 397 --outSAMtype BAM SortedByCoordinate --outSAMstrandField intronMotif --outFilterIntronMotifs 398
RemoveNoncanonical". The subread-1.6.1 package (featureCounts) was used to derive gene 399 counts given the following parameters: "-s 2 -t exon -g gene_name". Differential expression 400 analysis and data normalization was performed using DESeq2-1.16.1 with an adjusted p-value 401 threshold of 0.05 within an R-3.4.1 environment. Heatmaps were created using the pheatmap R 402 package 37-39 . 403 404
Data acquisition and statistical analysis 405
The prognostic assessment of septin-2, -7 and -9 in the panel of different cancers was conducted 406
using Human Protein Atlas tools. Alternatively, R2 genome.org tools were employed to determine 407 the impact of septins enrichment on the survival prospects. P values less than 0.05 were 408 considered significant. The relative tumor sizes in the naïve vs treat groups were calculated using 409
GraphPrism8 using one-way annova settings. P values less than 0.05 were considered significant. 410 411 412
Discussion 413 414
Data continue to emerge on the association of septins with malignancies, making identification of 415 septin-targeted therapies crucial to block the aberrant septin functions in cancer cells. Considering 416
FCF that essentially strengthens septin-2 40 as the starting point, we have developed UR214-9, a 417 small molecule which dismantles septin-2 and -9 filamental assembly in cancer cells without killing 418 the cells or altering the septins protein levels in the cells. To our best knowledge, this is the first 419 description of a pharmacologic approach to disrupt septin's structure in cells. We considered that 420 disrupting oligomeric septin filamental structures via UR214-9 treatment will be the key to impact 421 cytokinesis and control the proliferation of cancer cells. Not only did the disruption of septin 422
filaments by UR214-9 reduce the proliferation of pancreatic cancer cells (and of breast, ovarian 423 endometrial, lung and kidney cancers; some data not shown) in vitro, xenografted tumors of 424 breast, ovarian, pancreatic and lung malignancies (data not shown) treated with UR214-9 also 425
showed reduction in tumor growth. Interestingly, the combination with Herceptin led to stronger 426 control over HER2 positive SKOV-3 xenograft's growth (Figure-6D ). 427
Enhancement in antitumor effects of Herceptin via co-treatment with UR214-9 in HER2 428
positive ovarian cancer xenograft model is stemming likely from the association of septin-2 with 429 HER2. Septin-2 is shown to maintain HER2 signaling in cancer cells 27 . Septins protect and 430 stabilize HER2 receptor at the plasma membrane of tumor cells to perpetuate the HER2 431 orchestrated oncogenic signaling and tumorigenesis 27 . It is anticipated that targeting septins can 432
improve the survival rate of HER2 positive breast, pancreatic and other malignancies such as 433 ovarian and lung. HER2 overexpression leads to aggressive breast malignancy and poor patient 434 survival 41 . Current repertoire of therapies for HER2+ malignancies are inadequate. More than 60% 435 of HER2+ breast cancer patients do not respond to trastuzumab treatment and resistance to the 436 treatment develops rapidly in virtually all patients 42 . Further, the inability of trastuzumab to 437 penetrate solid breast tumors to block secreted (truncated) forms of HER2, that promote 438 resistance and metastasis, limits its usefulness in providing a complete and lasting control over 439
HER2 orchestrated breast tumor growth 43 . Similarly, treating or preventing brain metastases in 440 patients with HER2+ breast cancer is challenging 44 , particularly in the post-trastuzumab phase of 441 treatment. About two-thirds of patients develop brain metastases despite control or response of 442 their extracranial disease to trastuzumab 45 . Because trastuzumab does not penetrate the central 443
nervous system, the brain may serve as a sanctuary site 46 . A blood-brain barrier (BBB) penetrant 444 drug would be required to better control brain metastases in patients with HER2 +positive cancers. 445
UR214-9 carries the structural attributes of small polar surface area signatures (calculated for 446 UR214-9=53.49 vs <90 required to cross BBB) that would facilitate penetration through the BBB. 447
UR214-9, therefore, may improve outcomes of patients with brain metastases from HER2+ 448 cancers.
449
Signaling associations of septins are not fully understood. To determine signaling 450 association of septins and perturbations that UR214-9 treatment mounts, we conducted global 451
rna-seq analyses of breast and pancreatic cancer cells treated with UR214-9 and, as a 452
comparator, afatinib, a HER2 targeted therapy. As shown in Figure-7 , afatinib treatment clearly 453
had the most impact on the transcriptional profile of PANC-1 cells, while treatment with DMSO 454 and UR214-9 did not have much effect on the transcriptome. The lack of differentially expressed 455 genes between the UR214-9 treatment and control suggests that the mode of action of UR214-9 456
is non-transcriptional, and treatment with UR214-9 does not appear to elicit a gross transcriptional 457 response.
458
Taken together, this study demonstrates that aberrant septins expression indicates poor 459 prognoses among patients with cancer. UR214-9 is the first prototype of a small molecule that 460
can induce septin-2 and -9 filamental catastrophe, a pharmacologic and cytoskeletal response of 461 the cells not described before, to control cancer cell proliferation and tumor growth. Moreover, an 462
important pharmacologic feature of UR214-9 is the benefits of limited off-target engagements. As 463
shown in Figure-7 , compared to afatinib, an EGFR targeted therapy that affected gene expression 464 of over 1200 genes in JIMT-1 breast cancer cells, UR214-9 treatment even at 100-fold higher 465 dose affected less than 20 genes significantly. Although UR214-9 is a close structural analog of 466 FCF, UR214-9 differs significantly from FCF pharmacologically. While FCF is shown to 467 strengthen septin-2, UR214-9 dismantles septin-2 and septin-9 filamental assembly. ICM scores 468 calculated through molecular docking indicated greater binding affinity of UR214-9 with septin-469 2:septin-2 dimer complex than FCF. To the best of our knowledge, other than FCF, which is 470
clinically unfit due to the weak pharmacologic effects, off-target effects and functions associated 471
with strengthening the septin-2 filaments, UR214-9 is the only septin modulator described so far 472 that can dismantle septin's structural arrangement in nano molar concentrations (70nM-1uM).
473
Given the preliminary antitumor response in breast, pancreatic, ovarian and lung cancer xenograft 474 models (data not shown) and its therapeutic capabilities to significantly enhance the response of 475
Herceptin in HER2 expressing xenograft tumors it is apparent that dismantling septins is an 476 effective and clinically promising approach to prevent tumor growth, although doses, delivery 477
formulations and frequencies of administrations have to be optimized, and a synergistic or at least 478 an additive combinational agent has to be identified to achieve fuller control over the tumor growth. 479
Based on the promising outcome in combination with Herceptin, our laboratory is currently 480 evaluating the outcome of combination of UR214-9 with paclitaxel and Herceptin in breast cancer 481 models to increase the clinical utilities of UR214-9 .  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504 cancer patients using the data and tools available at the Human Protein Atlas or at R2-R2-514
Genomics Analysis and Visualization Platform show that septin-2 enrichment correlates with 515 decreased survival among pancreatic, breast and ovarian cancer patients. Septin-7 and -9 516 enrichment was associated with increased mortality as well (see supplementary Figure-1 Signaling Technology Inc., catalog number: 4290); pSTAT-3 (Cell Signaling Technology Inc., 713 catalog number: 9145p), STAT-3 (Cell Signaling Technology Inc., catalog number: 4904), AKT 714
(Cell Signaling Technology Inc., catalog number: 9272) and GAPDH antibodies (Cell Signaling 715
Technology Inc., catalog number: 2118s). (C): MDA-MB-231, JIMT-1 and MCF-7 cells were 716 treated with DMSO or UR214-9 (10 and 30µM) for 24 hours. The cells were lysed, immunoblotted 717
and probed with HER2 (Cell Signaling Technology Inc, catalog number: 4290) and phospho-718
STAT-3 (Cell Signaling Technology Inc., catalog number: 9145p) antibodies. (D): HER2 719 expressing SKOV-3 cells (500,000 cells/animals) were implanted in the right flanks of NSG mice 720 subcutaneously. When palpable, mice in groups (n=5 each) were treated with vehicle, UR214-9 721 (25mg/kg, M-F, I.P.), Herceptin (10mg/kg, M, I.P.). Fourth group was treated with both UR214-9 722 (25mg/kg, M-F, I.P.) and Herceptin (10mg/kg, M, I.P). Tumor sizes were measured on regular 723 intervals using a digital caliper. Longest length and width were recorded. Tumor volumes was 724 calculated using formula (L*W^2)*0.5 where L represents longest diameter and W stands for width 725 of the tumors measured through a digital caliper. Treatment was stopped on day-27 th and tumor 726 sizes were measured on the days indicated. On the day-53 rd since inoculation, mice were 727 euthanized and tumors were harvested. Tumor weights were recorded using a calibrated balance. 728
The statistical analyses were performed using Graph Prims 8.1.1.T-test analyses among groups 729
were performed using Graph Prism 8.1.1. version and p<0.05 was considered significant. Day-730 22: vehicle vs UR214-9: p=0.0035**; vehicle vs Herceptin: p=0.0011**; vehicle vs UR214-731 9+Herceptin: p=0.0001***; UR214-9 vs UR214-9+Herceptin: p=0.0059**; Herceptin vs UR214-732 9+Herceptin: p=0.049*. Day-27: vehicle vs UR214-9: p=0.0004***; vehicle vs Herceptin: 733 p=0.0002***; vehicle vs UR214-9+Herceptin: p<0.0001**** .  734  735  736  737  738  739  740  741  742  743  744  745  746  747  748  749  750 763  764  765  766  767  768  769  770  771  772  773  774 
